Norgine Ventures completes financing round with Impress

Impress is a privately owned digital orthodontic company, founded in 2019, based in Spain, that offers clear aligner orthodontic treatments in Europe and in the US. The Company has developed a proprietary, vertically-integrated technology platform powered by AI and ML software that helps organise and optimise the treatment journey. The orthodontic treatments are provided via […]

Norgine Ventures completes financing round with Inovus Medical

Inovus Medical, which is a privately owned UK company founded in 2012, based in St Helens that designs, manufactures, and sells surgical training devices, which are used by training surgeons to develop and improve their skills in general surgery, urology, obstetrics and gynaecology. The Company’s product portfolio consists of six laparoscopic simulators, two hysteroscopy simulators […]

Norgine Ventures completes financing with Lunaphore

Lunaphore Technologies SA, a privately owned Swiss company spun out from EPFL, develops automated tissue stainers which enable translational research laboratories to rapidly generate highly-multiplexed spatial biology assays using standard antibody libraries, with no conjugation or barcoding needed. Lunaphore’s most advanced solution, the COMET, is a fully automated sequential multiplex instrument, able to carry out […]

Norgine Ventures completes financing with Alesi

Alesi Surgical Limited, a privately owned Welsh company, is the developer of the UltravisionTM system that uses electrostatic technology to manage surgical smoke and bioaerosols which are generated by modern surgical cutting instruments during surgery, reducing the exposure level for surgeons and surgical teams. The company is partnered with Olympus Corporation of the Americas, for […]

Norgine Ventures completes financing with ImaginAb

ImaginAb, a privately owned biotechnology company based in Los Angeles, USA, is specialised in engineering of antibody fragments. The company’s lead program, 89Zr-Df-crefmirlimab, a PET imaging agent targeting CD8+ T cells, is currently in Phase II clinical trials. ImaginAb has signed a multi-party collaboration agreement with Pfizer, Astra Zeneca and Takeda for furthering the clinical development of […]

Norgine Ventures completes €3 million financing with PathoQuest

LONDON, UK. 05 September 2019, 08:00 BST. Norgine Ventures announced today that it has provided financing of up to €3 million to PathoQuest, a company using proprietary Next Generation Sequencing (NGS) based testing to improve pathogen detection. The company, a spin-out from Institut Pasteur, is based in Paris, France. PathoQuest provides services to the biopharmaceutical […]